Common Fundamentals of Psoriasis and Depression
DOI:
https://doi.org/10.2340/actadv.v101.565Keywords:
psoriasis, depression, psychological comorbidity, inflammation, pathophysiologic link, depression screening toolsAbstract
Psoriasis is an inflammatory, immune-mediated disease that is frequently associated with psychological comorbidities such as depression. The stigma patients feel because of the appearance of their skin may contribute to the high psycho-social burden of psoriasis. However, there is emerging evidence that overlapping biological mechanisms are, to a substantial degree, responsible for the close interaction between psoriasis and depression. Increased proinflammatory mediators, such as C-reactive protein or interleukin-6, are present in both psoriasis and depression, indicating that inflammation may represent a pathophysiological link between the diseases. Anti-inflammatory biologic therapies treat the clinical manifestations of psoriasis, but might also play a significant role in reducing associated depressive symptoms in patients with psoriasis. Comparison between single studies focusing on the change in depressive symptoms in psoriasis is limited by inconsistency in the depression screening tools applied.
Downloads
References
Schafer I, Rustenbach SJ, Radtke M, Augustin J, Glaeske G, Augustin M. Epidemiologie der Psoriasis in Deutschland - Auswertung von Sekundärdaten einer gesetzlichen Krankenversicherung. Gesundheitswesen 2011; 73: 308-313.
https://doi.org/10.1055/s-0030-1252022 DOI: https://doi.org/10.1055/s-0030-1252022
Tribo MJ, Turroja M, Castano-Vinyals G, Bulbena A, Ros E, Garcia-Martinez P, et al. Patients with moderate to severe psoriasis associate with higher risk of depression and anxiety symptoms: results of a multivariate study of 300 Spanish individuals with psoriasis. Acta Derm Venereol 2019; 99: 417-422.
https://doi.org/10.2340/00015555-3114 DOI: https://doi.org/10.2340/00015555-3114
Kurd SK, Troxel AB, Crits-Christoph P, Gelfand JM. The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study. Arch Dermatol 2010; 146: 891-895.
https://doi.org/10.1001/archdermatol.2010.186 DOI: https://doi.org/10.1001/archdermatol.2010.186
Dalgard FJ, Gieler U, Tomas-Aragones L, Lien L, Poot F, Jemec GBE, et al. The psychological burden of skin diseases: a cross-sectional multicenter study among dermatological out-patients in 13 European countries. J Invest Dermatol 2015; 135: 984-991.
https://doi.org/10.1038/jid.2014.530 DOI: https://doi.org/10.1038/jid.2014.530
Lamb RC, Matcham F, Turner MA, Rayner L, Simpson A, Hotopf M, et al. Screening for anxiety and depression in people with psoriasis: a cross-sectional study in a tertiary referral setting. Br J Dermatol 2017; 176: 1028-1034.
https://doi.org/10.1111/bjd.14833 DOI: https://doi.org/10.1111/bjd.14833
Dowlatshahi EA, Wakkee M, Arends LR, Nijsten T. The prevalence and odds of depressive symptoms and clinical depression in psoriasis patients: a systematic review and meta-analysis. J Invest Dermatol 2014; 134: 1542-1551.
https://doi.org/10.1038/jid.2013.508 DOI: https://doi.org/10.1038/jid.2013.508
Korman AM, Hill D, Alikhan A, Feldman SR. Impact and management of depression in psoriasis patients. Expert Opin Pharmacother 2016; 17: 147-152.
https://doi.org/10.1517/14656566.2016.1128894 DOI: https://doi.org/10.1517/14656566.2016.1128894
Fleming P, Bai JW, Pratt M, Sibbald C, Lynde C, Gulliver WP. The prevalence of anxiety in patients with psoriasis: a systematic review of observational studies and clinical trials. J Eur Acad Dermatol Venereol 2017; 31: 798-807.
https://doi.org/10.1111/jdv.13891 DOI: https://doi.org/10.1111/jdv.13891
Burden AD, Hilton Boon M, Leman J, Wilson H, Richmond R, Ormerod AD, et al. Diagnosis and management of psoriasis and psoriatic arthritis in adults: summary of SIGN guidance. BMJ 2010; 341: c5623.
https://doi.org/10.1136/bmj.c5623 DOI: https://doi.org/10.1136/bmj.c5623
Sondermann W, Schreiber A, Korber A, Fiege O, Scherbaum N, Benson S, et al. Psychosocial burden and body mass index are associated with dermatology-related quality of life in psoriasis patients. Eur J Dermatol 2020; 30: 140-147.
https://doi.org/10.1684/ejd.2020.3755 DOI: https://doi.org/10.1684/ejd.2020.3755
Sondermann W, Fiege O, Körber A, Scherbaum N. Psychological burden of psoriatic patients in a German university hospital dermatology department. J Dermatol 2020; 48: 794-806.
https://doi.org/10.1111/1346-8138.15721 DOI: https://doi.org/10.1111/1346-8138.15721
Radtke MA, Mrowietz U, Feuerhahn J, Harter M, von Kiedrowski R, Nast A, et al. Early detection of comorbidity in psoriasis: recommendations of the National Conference on Healthcare in Psoriasis. J Dtsch Dermatol Ges 2015; 13: 674-690.
https://doi.org/10.1111/ddg.12643 DOI: https://doi.org/10.1111/ddg.12643
Wu JJ, Feldman SR, Koo J, Marangell LB. Epidemiology of mental health comorbidity in psoriasis. J Dermatolog Treat 2018; 29: 487-495.
https://doi.org/10.1080/09546634.2017.1395800 DOI: https://doi.org/10.1080/09546634.2017.1395800
Jin W, Zhang S, Duan Y. Depression symptoms predict worse clinical response to etanercept treatment in psoriasis patients. Dermatology 2019; 235: 55-64.
https://doi.org/10.1159/000492784 DOI: https://doi.org/10.1159/000492784
Lakuta P, Marcinkiewicz K, Bergler-Czop B, Brzezinska-Wcislo L. How does stigma affect people with psoriasis? Postepy Dermatol Alergol 2017; 34: 36-41.
https://doi.org/10.5114/pdia.2016.62286 DOI: https://doi.org/10.5114/pdia.2016.62286
Walsh BT, Seidman SN, Sysko R, Gould M. Placebo response in studies of major depression: variable, substantial, and growing. JAMA 2002; 287: 1840-1847.
https://doi.org/10.1001/jama.287.14.1840 DOI: https://doi.org/10.1001/jama.287.14.1840
Oeljeschläger B, Müller-Oerlinghausen B. Wege zur Optimierung der individuellen antidepressiven Therapie. Dtsch Arztebl International 2004; 101: 1337-1340.
Schneider F, Härter M, Schorr S. S3-Leitlinie/Nationale Versorgungs-Leitlinie Unipolare Depression Springer-Verlag; 2017.
https://doi.org/10.1007/978-3-662-52906-5 DOI: https://doi.org/10.1007/978-3-662-52906-5
Beurel E, Toups M, Nemeroff CB. The bidirectional relationship of depression and inflammation: double trouble. Neuron 2020; 107: 234-256.
https://doi.org/10.1016/j.neuron.2020.06.002 DOI: https://doi.org/10.1016/j.neuron.2020.06.002
Miller AH, Raison CL. The role of inflammation in depression: from evolutionary imperative to modern treatment target. Nat Rev Immunol 2016; 16: 22-34.
https://doi.org/10.1038/nri.2015.5 DOI: https://doi.org/10.1038/nri.2015.5
Salvador AF, de Lima KA, Kipnis J. Neuromodulation by the immune system: a focus on cytokines. Nat Rev Immunol 2021; 21: 526-541.
https://doi.org/10.1038/s41577-021-00508-z DOI: https://doi.org/10.1038/s41577-021-00508-z
Roman M, Irwin MR. Novel neuroimmunologic therapeutics in depression: a clinical perspective on what we know so far. Brain Behav Immun 2020; 83: 7-21.
https://doi.org/10.1016/j.bbi.2019.09.016 DOI: https://doi.org/10.1016/j.bbi.2019.09.016
Howren MB, Lamkin DM, Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med 2009; 71: 171-186.
https://doi.org/10.1097/PSY.0b013e3181907c1b DOI: https://doi.org/10.1097/PSY.0b013e3181907c1b
Prather AA, Rabinovitz M, Pollock BG, Lotrich FE. Cytokine-induced depression during IFN-alpha treatment: the role of IL-6 and sleep quality. Brain Behav Immun 2009; 23: 1109-1116.
https://doi.org/10.1016/j.bbi.2009.07.001 DOI: https://doi.org/10.1016/j.bbi.2009.07.001
Lotrich FE, El-Gabalawy H, Guenther LC, Ware CF. The role of inflammation in the pathophysiology of depression: different treatments and their effects. J Rheumatol Suppl 2011; 88: 48-54.
https://doi.org/10.3899/jrheum.110903 DOI: https://doi.org/10.3899/jrheum.110903
Gimeno D, Kivimaki M, Brunner EJ, Elovainio M, De Vogli R, Steptoe A, et al. Associations of C-reactive protein and interleukin-6 with cognitive symptoms of depression: 12-year follow-up of the Whitehall II study. Psychol Med 2009; 39: 413-423.
https://doi.org/10.1017/S0033291708003723 DOI: https://doi.org/10.1017/S0033291708003723
Raison CL, Borisov AS, Majer M, Drake DF, Pagnoni G, Woolwine BJ, et al. Activation of central nervous system inflammatory pathways by interferon-alpha: relationship to monoamines and depression. Biol Psychiatry 2009; 65: 296-303.
https://doi.org/10.1016/j.biopsych.2008.08.010 DOI: https://doi.org/10.1016/j.biopsych.2008.08.010
Gold SM, Kohler-Forsberg O, Moss-Morris R, Mehnert A, Miranda JJ, Bullinger M, et al. Comorbid depression in medical diseases. Nat Rev Dis Primers 2020; 6: 69.
https://doi.org/10.1038/s41572-020-0200-2 DOI: https://doi.org/10.1038/s41572-020-0200-2
Dickens C, Creed F. The burden of depression in patients with rheumatoid arthritis. Rheumatology (Oxford) 2001; 40: 1327-1330.
https://doi.org/10.1093/rheumatology/40.12.1327 DOI: https://doi.org/10.1093/rheumatology/40.12.1327
Moulton CD, Pavlidis P, Norton C, Norton S, Pariante C, Hayee B, et al. Depressive symptoms in inflammatory bowel disease: an extraintestinal manifestation of inflammation? Clin Exp Immunol 2019; 197: 308-318.
https://doi.org/10.1111/cei.13276 DOI: https://doi.org/10.1111/cei.13276
Dantzer R. Neuroimmune interactions: from the brain to the immune system and vice versa. Physiol Rev 2018; 98: 477-504.
https://doi.org/10.1152/physrev.00039.2016 DOI: https://doi.org/10.1152/physrev.00039.2016
Kleyn CE, Talbot PS, Mehta NN, Sampogna F, Bundy C, Ashcroft DM, et al. Psoriasis and mental health workshop report: exploring the links between psychosocial factors, psoriasis, neuroinflammation and cardiovascular disease risk. Acta Derm Venereol 2020; 100: adv00020.
https://doi.org/10.2340/00015555-3375 DOI: https://doi.org/10.2340/00015555-3375
Benson S, Brinkhoff A, Lueg L, Roderigo T, Kribben A, Wilde B, et al. Effects of acute systemic inflammation on the interplay between sad mood and affective cognition. Transl Psychiatry 2017; 7: 1281.
https://doi.org/10.1038/s41398-017-0043-0 DOI: https://doi.org/10.1038/s41398-017-0043-0
Lasselin J, Schedlowski M, Karshikoff B, Engler H, Lekander M, Konsman JP. Comparison of bacterial lipopolysaccharide-induced sickness behavior in rodents and humans: Relevance for symptoms of anxiety and depression. Neurosci Biobehav Rev 2020; 115: 15-24.
https://doi.org/10.1016/j.neubiorev.2020.05.001 DOI: https://doi.org/10.1016/j.neubiorev.2020.05.001
Lasselin J, Lekander M, Benson S, Schedlowski M, Engler H. Sick for science: experimental endotoxemia as a translational tool to develop and test new therapies for inflammation-associated depression. Mol Psychiatry 2021; 26: 3672-3683.
https://doi.org/10.1038/s41380-020-00869-2 DOI: https://doi.org/10.1038/s41380-020-00869-2
Najjar S, Pearlman DM, Devinsky O, Najjar A, Zagzag D. Neurovascular unit dysfunction with blood-brain barrier hyperpermeability contributes to major depressive disorder: a review of clinical and experimental evidence. J Neuroinflammation 2013; 10: 142.
https://doi.org/10.1186/1742-2094-10-142 DOI: https://doi.org/10.1186/1742-2094-10-142
Anisman H, Merali Z, Hayley S. Neurotransmitter, peptide and cytokine processes in relation to depressive disorder: comorbidity between depression and neurodegenerative disorders. Prog Neurobiol 2008; 85: 1-74.
https://doi.org/10.1016/j.pneurobio.2008.01.004 DOI: https://doi.org/10.1016/j.pneurobio.2008.01.004
Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 2008; 9: 46-56.
https://doi.org/10.1038/nrn2297 DOI: https://doi.org/10.1038/nrn2297
Goehler LE, Gaykema RP, Hansen MK, Anderson K, Maier SF, Watkins LR. Vagal immune-to-brain communication: a visceral chemosensory pathway. Auton Neurosci 2000; 85: 49-59.
https://doi.org/10.1016/S1566-0702(00)00219-8 DOI: https://doi.org/10.1016/S1566-0702(00)00219-8
Raison CL, Rutherford RE, Woolwine BJ, Shuo C, Schettler P, Drake DF, et al. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry 2013; 70: 31-41.
https://doi.org/10.1001/2013.jamapsychiatry.4 DOI: https://doi.org/10.1001/2013.jamapsychiatry.4
Khandaker GM, Oltean BP, Kaser M, Dibben CRM, Ramana R, Jadon DR, et al. Protocol for the insight study: a randomised controlled trial of single-dose tocilizumab in patients with depression and low-grade inflammation. BMJ Open 2018; 8: e025333.
https://doi.org/10.1136/bmjopen-2018-025333 DOI: https://doi.org/10.1136/bmjopen-2018-025333
Kohler O, Krogh J, Mors O, Benros ME. Inflammation in depression and the potential for anti-inflammatory treatment. Curr Neuropharmacol 2016; 14: 732-742.
https://doi.org/10.2174/1570159X14666151208113700 DOI: https://doi.org/10.2174/1570159X14666151208113700
Boehncke WH. Systemic inflammation and cardiovascular comorbidity in psoriasis patients: causes and consequences. Front Immunol 2018; 9: 579.
https://doi.org/10.3389/fimmu.2018.00579 DOI: https://doi.org/10.3389/fimmu.2018.00579
Koo J, Marangell LB, Nakamura M, Armstrong A, Jeon C, Bhutani T, et al. Depression and suicidality in psoriasis: review of the literature including the cytokine theory of depression. J Eur Acad Dermatol Venereol 2017; 31: 1999-2009.
https://doi.org/10.1111/jdv.14460 DOI: https://doi.org/10.1111/jdv.14460
Patel N, Nadkarni A, Cardwell LA, Vera N, Frey C, Patel N, et al. Psoriasis, depression, and inflammatory overlap: a review. Am J Clin Dermatol 2017; 18: 613-620.
https://doi.org/10.1007/s40257-017-0279-8 DOI: https://doi.org/10.1007/s40257-017-0279-8
Dowlatshahi EA, van der Voort EA, Arends LR, Nijsten T. Markers of systemic inflammation in psoriasis: a systematic review and meta-analysis. Br J Dermatol 2013; 169: 266-282.
https://doi.org/10.1111/bjd.12355 DOI: https://doi.org/10.1111/bjd.12355
Bai F, Zheng W, Dong Y, Wang J, Garstka MA, Li R, et al. Serum levels of adipokines and cytokines in psoriasis patients: a systematic review and meta-analysis. Oncotarget 2018; 9: 1266-1278.
https://doi.org/10.18632/oncotarget.22260 DOI: https://doi.org/10.18632/oncotarget.22260
Zhou XY, Bao J, Huang B, Jin Y. Association between plasma interleukin-17 levels and risk of psoriasis: a meta-analysis. Clin Exp Dermatol 2017; 42: 161-166.
https://doi.org/10.1111/ced.13033 DOI: https://doi.org/10.1111/ced.13033
El-Moaty Zaher HA, El-Komy MHM, Hegazy RA, Mohamed El Khashab HA, Ahmed HH. Assessment of interleukin-17 and vitamin D serum levels in psoriatic patients. J Am Acad Dermatol 2013; 69: 840-842.
https://doi.org/10.1016/j.jaad.2013.07.026 DOI: https://doi.org/10.1016/j.jaad.2013.07.026
Lynde CW, Poulin Y, Vender R, Bourcier M, Khalil S. Interleukin 17A: toward a new understanding of psoriasis pathogenesis. J Am Acad Dermatol 2014; 71: 141-150.
https://doi.org/10.1016/j.jaad.2013.12.036 DOI: https://doi.org/10.1016/j.jaad.2013.12.036
Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med 2009; 361: 496-509.
https://doi.org/10.1056/NEJMra0804595 DOI: https://doi.org/10.1056/NEJMra0804595
Kim J, Tomalin L, Lee J, Fitz LJ, Berstein G, Correa-da Rosa J, et al. Reduction of inflammatory and cardiovascular proteins in the blood of patients with psoriasis: differential responses between tofacitinib and etanercept after 4 weeks of treatment. J Invest Dermatol 2018; 138: 273-281.
https://doi.org/10.1016/j.jid.2017.08.040 DOI: https://doi.org/10.1016/j.jid.2017.08.040
Mattei PL, Corey KC, Kimball AB. Cumulative life course impairment: evidence for psoriasis. Curr Probl Dermatol 2013; 44: 82-90.
https://doi.org/10.1159/000350008 DOI: https://doi.org/10.1159/000350008
Pietrzak D, Pietrzak A, Grywalska E, Kicinski P, Rolinski J, Donica H, et al. Serum concentrations of interleukin 18 and 25-hydroxyvitamin D3 correlate with depression severity in men with psoriasis. PLoS One 2018; 13: e0201589.
https://doi.org/10.1371/journal.pone.0201589 DOI: https://doi.org/10.1371/journal.pone.0201589
Murray ML, Bergstresser PR, Adams-Huet B, Cohen JB. Relationship of psoriasis severity to obesity using same-gender siblings as controls for obesity. Clin Exp Dermatol 2009; 34: 140-144.
https://doi.org/10.1111/j.1365-2230.2008.02791.x DOI: https://doi.org/10.1111/j.1365-2230.2008.02791.x
Jensen P, Skov L. Psoriasis and obesity. Dermatology 2016; 232: 633-639.
https://doi.org/10.1159/000455840 DOI: https://doi.org/10.1159/000455840
Pona A, Haidari W, Kolli SS, Feldman SR. Diet and psoriasis. Dermatol Online J 2019; 25: 13030/qt1p37435s.
https://doi.org/10.5070/D3252042883 DOI: https://doi.org/10.5070/D3252042883
Luppino FS, de Wit LM, Bouvy PF, Stijnen T, Cuijpers P, Penninx BW, et al. Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies. Arch Gen Psychiatry 2010; 67: 220-229.
https://doi.org/10.1001/archgenpsychiatry.2010.2 DOI: https://doi.org/10.1001/archgenpsychiatry.2010.2
Boehncke WH. Psoriasis and psoriatic arthritis: flip sides of the coin? Acta Derm Venereol 2016; 96: 436-441.
https://doi.org/10.2340/00015555-2385 DOI: https://doi.org/10.2340/00015555-2385
Wu CY, Chang YT, Juan CK, Shen JL, Lin YP, Shieh JJ, et al. Depression and insomnia in patients with psoriasis and psoriatic arthritis taking tumor necrosis factor antagonists. Medicine (Baltimore) 2016; 95: e3816.
https://doi.org/10.1097/MD.0000000000003816 DOI: https://doi.org/10.1097/MD.0000000000003816
Husted JA, Thavaneswaran A, Chandran V, Eder L, Rosen CF, Cook RJ, et al. Cardiovascular and other comorbidities in patients with psoriatic arthritis: a comparison with patients with psoriasis. Arthritis Care Res 2011; 63: 1729-1735.
https://doi.org/10.1002/acr.20627 DOI: https://doi.org/10.1002/acr.20627
Asahina A, Umezawa Y, Yanaba K, Nakagawa H. Serum C-reactive protein levels in Japanese patients with psoriasis and psoriatic arthritis: long-term differential effects of biologics. J Dermatol 2016; 43: 779-784.
https://doi.org/10.1111/1346-8138.13213 DOI: https://doi.org/10.1111/1346-8138.13213
Boehncke S, Salgo R, Garbaraviciene J, Beschmann H, Hardt K, Diehl S, et al. Effective continuous systemic therapy of severe plaque-type psoriasis is accompanied by amelioration of biomarkers of cardiovascular risk: results of a prospective longitudinal observational study. J Eur Acad Dermatol Venereol 2011; 25: 1187-1193.
https://doi.org/10.1111/j.1468-3083.2010.03947.x DOI: https://doi.org/10.1111/j.1468-3083.2010.03947.x
Gkalpakiotis S, Arenbergerova M, Gkalpakioti P, Potockova J, Arenberger P, Kraml P. Long-term impact of adalimumab therapy on biomarkers of systemic inflammation in psoriasis: results of a 2 year study. Dermatol Ther 2020; 33: e14110.
https://doi.org/10.1111/dth.14110 DOI: https://doi.org/10.1111/dth.14110
Pincelli C, Schafer PH, French LE, Augustin M, Krueger JG. Mechanisms underlying the clinical effects of apremilast for psoriasis. J Drugs Dermatol 2018; 17: 835-840.
Lockshin B, Balagula Y, Merola JF. Interleukin 17, inflammation, and cardiovascular risk in patients with psoriasis. J Am Acad Dermatol 2018; 79: 345-352.
https://doi.org/10.1016/j.jaad.2018.02.040 DOI: https://doi.org/10.1016/j.jaad.2018.02.040
Roubille C, Richer V, Starnino T, McCourt C, McFarlane A, Fleming P, et al. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis 2015; 74: 480-489.
https://doi.org/10.1136/annrheumdis-2014-206624 DOI: https://doi.org/10.1136/annrheumdis-2014-206624
Wu JJ, Guérin A, Sundaram M, Dea K, Cloutier M, Mulani P. Cardiovascular event risk assessment in psoriasis patients treated with tumor necrosis factor-α inhibitors versus methotrexate. J Am Acad Dermatol 2017; 76: 81-90.
https://doi.org/10.1016/j.jaad.2016.07.042 DOI: https://doi.org/10.1016/j.jaad.2016.07.042
Elnabawi YA, Dey AK, Goyal A, Groenendyk JW, Chung JH, Belur AD, et al. Coronary artery plaque characteristics and treatment with biologic therapy in severe psoriasis: results from a prospective observational study. Cardiovasc Res 2019; 115: 721-728.
https://doi.org/10.1093/cvr/cvz009 DOI: https://doi.org/10.1093/cvr/cvz009
von Stebut E, Reich K, Thaçi D, Koenig W, Pinter A, Körber A, et al. Impact of secukinumab on endothelial dysfunction and other cardiovascular disease parameters in psoriasis patients over 52 weeks. J Invest Dermatol 2019; 139: 1054-1062.
https://doi.org/10.1016/j.jid.2018.10.042 DOI: https://doi.org/10.1016/j.jid.2018.10.042
Malhotra SK, Mehta V. Role of stressful life events in induction or exacerbation of psoriasis and chronic urticaria. Indian J Dermatol Venereol Leprol 2008; 74: 594-599.
https://doi.org/10.4103/0378-6323.45100 DOI: https://doi.org/10.4103/0378-6323.45100
Ayasse MT, Buddenkotte J, Alam M, Steinhoff M. Role of neuroimmune circuits and pruritus in psoriasis. Exp Dermatol 2020; 29: 414-426.
https://doi.org/10.1111/exd.14071 DOI: https://doi.org/10.1111/exd.14071
Langley RG, Feldman SR, Han C, Schenkel B, Szapary P, Hsu MC, et al. Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial. J Am Acad Dermatol 2010; 63: 457-465.
https://doi.org/10.1016/j.jaad.2009.09.014 DOI: https://doi.org/10.1016/j.jaad.2009.09.014
Gordon KB, Armstrong AW, Han C, Foley P, Song M, Wasfi Y, et al. Anxiety and depression in patients with moderate-to-severe psoriasis and comparison of change from baseline after treatment with guselkumab vs. adalimumab: results from the Phase 3 VOYAGE 2 study. J Eur Acad Dermatol Venereol 2018; 32: 1940-1949.
https://doi.org/10.1111/jdv.15012 DOI: https://doi.org/10.1111/jdv.15012
Papp KA, Reich K, Paul C, Blauvelt A, Baran W, Bolduc C, et al. A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis. Br J Dermatol 2016; 175: 273-286.
https://doi.org/10.1111/bjd.14493 DOI: https://doi.org/10.1111/bjd.14493
Wittenberg GM, Stylianou A, Zhang Y, Sun Y, Gupta A, Jagannatha PS, et al. Effects of immunomodulatory drugs on depressive symptoms: a mega-analysis of randomized, placebo-controlled clinical trials in inflammatory disorders. Mol Psychiatry 2020; 25: 1275-1285.
https://doi.org/10.1038/s41380-019-0471-8 DOI: https://doi.org/10.1038/s41380-019-0471-8
Kappelmann N, Lewis G, Dantzer R, Jones PB, Khandaker GM. Antidepressant activity of anti-cytokine treatment: a systematic review and meta-analysis of clinical trials of chronic inflammatory conditions. Mol Psychiatry 2018; 23: 335-343.
https://doi.org/10.1038/mp.2016.167 DOI: https://doi.org/10.1038/mp.2016.167
Mrowietz U, Kragballe K, Reich K, Spuls P, Griffiths CE, Nast A, et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res 2011; 303: 1-10.
https://doi.org/10.1007/s00403-010-1080-1 DOI: https://doi.org/10.1007/s00403-010-1080-1
Norris D, Photiou L, Tacey M, Dolianitis C, Varigos G, Foley P, et al. Biologics and dermatology life quality index (DLQI) in the Australasian psoriasis population. J Dermatolog Treat 2017; 28: 731-736.
https://doi.org/10.1080/09546634.2017.1329501 DOI: https://doi.org/10.1080/09546634.2017.1329501
Mermin D, Boursault L, Milpied B, Taieb A, Ezzedine K, Seneschal J. DLQI as a major criterion for introduction of systemic agents in patients with mild psoriasis. J Eur Acad Dermatol Venereol 2016; 30: 1961-1964.
https://doi.org/10.1111/jdv.13803 DOI: https://doi.org/10.1111/jdv.13803
Both H, Essink-Bot ML, Busschbach J, Nijsten T. Critical review of generic and dermatology-specific health-related quality of life instruments. J Invest Dermatol 2007; 127: 2726-2739.
https://doi.org/10.1038/sj.jid.5701142 DOI: https://doi.org/10.1038/sj.jid.5701142
Lebwohl M, Papp K, Han C, Schenkel B, Yeilding N, Wang Y, et al. Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial. Br J Dermatol 2010; 162: 137-146.
https://doi.org/10.1111/j.1365-2133.2009.09491.x DOI: https://doi.org/10.1111/j.1365-2133.2009.09491.x
Papp KA, Leonardi C, Menter A, Ortonne JP, Krueger JG, Kricorian G, et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med 2012; 366: 1181-1189.
https://doi.org/10.1056/NEJMoa1109017 DOI: https://doi.org/10.1056/NEJMoa1109017
Sticherling M, Mrowietz U, Augustin M, Thaci D, Melzer N, Hentschke C, et al. Secukinumab is superior to fumaric acid esters in treating patients with moderate-to-severe plaque psoriasis who are naive to systemic treatments: results from the randomized controlled PRIME trial. Br J Dermatol 2017; 177: 1024-1032.
https://doi.org/10.1111/bjd.15707 DOI: https://doi.org/10.1111/bjd.15707
Leman J, Walton S, Layton AM, Ward KA, McBride S, Cliff S, et al. The real world impact of adalimumab on quality of life and the physical and psychological effects of moderate-to-severe psoriasis: a UK prospective, multicenter, observational study. J Dermatolog Treat 2020; 31: 213-221.
https://doi.org/10.1080/09546634.2019.1592096 DOI: https://doi.org/10.1080/09546634.2019.1592096
Papp K, Reich K, Paul C, Blauvelt A, Toth D, Langley R, et al. Improvements in depression and anxiety with brodalumab therapy in AMAGINE-1, a phase 3 study for moderate to severe plaque psoriasis. J Am Acad Dermatol 2016; 74: AB254.
https://doi.org/10.1016/j.jaad.2016.02.989 DOI: https://doi.org/10.1016/j.jaad.2016.02.989
Reich K, Armstrong AW, Foley P, Song M, Miller M, Shen YK, et al. Maintenance of response through up to 4 years of continuous guselkumab treatment of psoriasis in the VOYAGE 2 Phase 3 study. Am J Clin Dermatol 2020; 21: 881-890.
https://doi.org/10.1007/s40257-020-00555-7 DOI: https://doi.org/10.1007/s40257-020-00555-7
Dauden E, Griffiths CE, Ortonne JP, Kragballe K, Molta CT, Robertson D, et al. Improvements in patient-reported outcomes in moderate-to-severe psoriasis patients receiving continuous or paused etanercept treatment over 54 weeks: the CRYSTEL study. J Eur Acad Dermatol Venereol 2009; 23: 1374-1382.
https://doi.org/10.1111/j.1468-3083.2009.03321.x DOI: https://doi.org/10.1111/j.1468-3083.2009.03321.x
Gniadecki R, Robertson D, Molta CT, Freundlich B, Pedersen R, Li W, et al. Self-reported health outcomes in patients with psoriasis and psoriatic arthritis randomized to two etanercept regimens. J Eur Acad Dermatol Venereol 2012; 26: 1436-1443.
https://doi.org/10.1111/j.1468-3083.2011.04308.x DOI: https://doi.org/10.1111/j.1468-3083.2011.04308.x
Yang A, Xin X, Yang W, Li M, Yang W, Li L, et al. Etanercept reduces anxiety and depression in psoriasis patients, and sustained depression correlates with reduced therapeutic response to etanercept. Ann Dermatol Venereol 2019; 146: 363-371.
https://doi.org/10.1016/j.annder.2019.03.002 DOI: https://doi.org/10.1016/j.annder.2019.03.002
Tyring S, Gottlieb A, Papp K, Gordon K, Leonardi C, Wang A, et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 2006; 367: 29-35.
https://doi.org/10.1016/S0140-6736(05)67763-X DOI: https://doi.org/10.1016/S0140-6736(05)67763-X
Gelfand JM, Kimball AB, Mostow EN, Chiou CF, Patel V, Xia HA, et al. Patient-reported outcomes and health-care resource utilization in patients with psoriasis treated with etanercept: continuous versus interrupted treatment. Value Health 2008; 11: 400-407.
https://doi.org/10.1111/j.1524-4733.2007.00251.x DOI: https://doi.org/10.1111/j.1524-4733.2007.00251.x
Menter A, Augustin M, Signorovitch J, Yu AP, Wu EQ, Gupta SR, et al. The effect of adalimumab on reducing depression symptoms in patients with moderate to severe psoriasis: a randomized clinical trial. J Am Acad Dermatol 2010; 62: 812-818.
https://doi.org/10.1016/j.jaad.2009.07.022 DOI: https://doi.org/10.1016/j.jaad.2009.07.022
Helmick CG, Lee-Han H, Hirsch SC, Baird TL, Bartlett CL. Prevalence of psoriasis among adults in the U.S.: 2003-2006 and 2009-2010 National Health and Nutrition Examination Surveys. Am J Prev Med 2014; 47: 37-45.
https://doi.org/10.1016/j.amepre.2014.02.012 DOI: https://doi.org/10.1016/j.amepre.2014.02.012
Cohen BE, Martires KJ, Ho RS. Psoriasis and the risk of depression in the US population: National Health and Nutrition Examination Survey 2009-2012. JAMA Dermatol 2016; 152: 73-79.
https://doi.org/10.1001/jamadermatol.2015.3605 DOI: https://doi.org/10.1001/jamadermatol.2015.3605
Lebowitz E, Lebwohl M. Review of suicide and depression in psoriasis and management of suicide warnings in patients treated with psoriasis drugs. SKIN 2019; 3: 72-81.
https://doi.org/10.25251/skin.3.2.39 DOI: https://doi.org/10.25251/skin.3.2.39
Dalgard FJ, Svensson Å, Gieler U, Tomas-Aragones L, Lien L, Poot F, et al. Dermatologists across Europe underestimate depression and anxiety: results from 3635 dermatological consultations. Br J Dermatol 2018; 179: 464-470.
https://doi.org/10.1111/bjd.16250 DOI: https://doi.org/10.1111/bjd.16250
Whooley MA, Avins AL, Miranda J, Browner WS. Case-finding instruments for depression. Two questions are as good as many. J Gen Intern Med 1997; 12: 439-445.
https://doi.org/10.1046/j.1525-1497.1997.00076.x DOI: https://doi.org/10.1046/j.1525-1497.1997.00076.x
Wohlrab J, Fiedler G, Gerdes S, Nast A, Philipp S, Radtke MA, et al. Recommendations for detection of individual risk for comorbidities in patients with psoriasis. Arch Dermatol Res 2013; 305: 91-98.
https://doi.org/10.1007/s00403-013-1318-9 DOI: https://doi.org/10.1007/s00403-013-1318-9
Trettin B, Feldman SR, Andersen F, Danbjorg DB, Agerskov H. A changed life: the life experiences of patients with psoriasis receiving biological treatment. Br J Dermatol 2020; 183: 516-523.
https://doi.org/10.1111/bjd.18876 DOI: https://doi.org/10.1111/bjd.18876
Kimball AB, Wu EQ, Guérin A, Yu AP, Tsaneva M, Gupta SR, et al. Risks of developing psychiatric disorders in pediatric patients with psoriasis. J Am Acad Dermatol 2012; 67: 651-657.
https://doi.org/10.1016/j.jaad.2011.11.948 DOI: https://doi.org/10.1016/j.jaad.2011.11.948
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2021 Stefanie Hölsken, Frederik Krefting, Manfred Schedlowski, Wiebke Sondermann
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
